Renin-angiotensin-aldosterone system inhibitors and COVID-19

Affiliations

¹ Department of Medicine (Quinn, Fralick, Zipursky, Stall), University of Toronto; Division of General Internal Medicine and Geriatrics (Quinn, Fralick, Stall), Sinai Health System; Institute of Health Policy, Management and Evaluation (Quinn, Zipursky, Stall), University of Toronto; Division of Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre, Toronto, Ont. kieran.quinn@sinaihealth.ca.
² Department of Medicine (Quinn, Fralick, Zipursky, Stall), University of Toronto; Division of General Internal Medicine and Geriatrics (Quinn, Fralick, Stall), Sinai Health System; Institute of Health Policy, Management and Evaluation (Quinn, Zipursky, Stall), University of Toronto; Division of Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre, Toronto, Ont.

Kieran L Quinn et al. CMAJ. 2020.

. 2020 May 19;192(20):E553-E554.

doi: 10.1503/cmaj.200619. Epub 2020 Apr 24.

¹ Department of Medicine (Quinn, Fralick, Zipursky, Stall), University of Toronto; Division of General Internal Medicine and Geriatrics (Quinn, Fralick, Stall), Sinai Health System; Institute of Health Policy, Management and Evaluation (Quinn, Zipursky, Stall), University of Toronto; Division of Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre, Toronto, Ont. kieran.quinn@sinaihealth.ca.
² Department of Medicine (Quinn, Fralick, Zipursky, Stall), University of Toronto; Division of General Internal Medicine and Geriatrics (Quinn, Fralick, Stall), Sinai Health System; Institute of Health Policy, Management and Evaluation (Quinn, Zipursky, Stall), University of Toronto; Division of Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre, Toronto, Ont.

No abstract available

Conflict of interest statement

Competing interests: None declared.

Good things come in threes (and sometimes fours): Update on renin-angiotensin-aldosterone system inhibitors and COVID-19.
Quinn KL, Fralick M, Zipursky JS, Stall NM. Quinn KL, et al. CMAJ. 2020 Jun 1;192(22):E611. doi: 10.1503/cmaj.75720. CMAJ. 2020. PMID: 32575050 Free PMC article. No abstract available.
Association between angiotensin blockade and COVID-19 severity in Hong Kong.
Cheung KS, Hung IFN, Leung WK. Cheung KS, et al. CMAJ. 2020 Jun 8;192(23):E635. doi: 10.1503/cmaj.75865. CMAJ. 2020. PMID: 32575056 Free PMC article. No abstract available.

1. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020. March 13 [Epub ahead of print]. 10.1001/jamainternmed.2020.0994. - DOI - PMC - PubMed
1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020. March 11 [Epub ahead of print]. 10.1016/S0140-6736(20)30566-3. - DOI - PMC - PubMed
1. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4103 patients with COVID-19 disease in New York City. medRxiv 2020. Apr. 11. 10.1101/2020.04.08.20057794 Available: www.medrxiv.org/content/10.1101/2020.04.08.20057794v1 (accessed 2020 Apr. 20). - DOI
1. Whelton PK, Carey RM. The 2017 clinical practice guideline for high blood pressure. JAMA 2017;318:2073–4. - PubMed
1. Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What is the evidence? JAMA 2020. Mar. 24 [Epub ahead of print]. 10.1001/jama.2020.4812. - DOI - PubMed